Title | Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Milner, JD, Vogel, TP, Forbes, L, Ma, CA, Stray-Pedersen, A, Niemela, JE, Lyons, JJ, Engelhardt, KR, Zhang, Y, Topcagic, N, Roberson, EDO, Matthews, H, Verbsky, JW, Dasu, T, Vargas-Hernandez, A, Varghese, N, McClain, KL, Karam, LB, Nahmod, K, Makedonas, G, Mace, EM, Sorte, HS, Perminow, G, V Rao, K, O'Connell, MP, Price, S, Su, HC, Butrick, M, McElwee, J, Hughes, JD, Willet, J, Swan, D, Xu, Y, Santibanez-Koref, M, Slowik, V, Dinwiddie, DL, Ciaccio, CE, Saunders, CJ, Septer, S, Kingsmore, SF, White, AJ, Cant, AJ, Hambleton, S, Cooper, MA |
Journal | Blood |
Volume | 125 |
Issue | 4 |
Pagination | 591-9 |
Date Published | 2015 Jan 22 |
ISSN | 1528-0020 |
Keywords | Adolescent, Adult, Autoimmune Diseases, Child, Child, Preschool, Female, Genetic Diseases, Inborn, Humans, Infant, Lymphoproliferative Disorders, Male, Mutation, Phosphorylation, STAT1 Transcription Factor, STAT3 Transcription Factor, STAT5 Transcription Factor, T-Lymphocytes, Regulatory |
Abstract | Germline loss-of-function mutations in the transcription factor signal transducer and activator of transcription 3 (STAT3) cause immunodeficiency, whereas somatic gain-of-function mutations in STAT3 are associated with large granular lymphocytic leukemic, myelodysplastic syndrome, and aplastic anemia. Recently, germline mutations in STAT3 have also been associated with autoimmune disease. Here, we report on 13 individuals from 10 families with lymphoproliferation and early-onset solid-organ autoimmunity associated with 9 different germline heterozygous mutations in STAT3. Patients exhibited a variety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic, and/or endocrine dysfunction), infections, and short stature. Functional analyses demonstrate that these mutations confer a gain-of-function in STAT3 leading to secondary defects in STAT5 and STAT1 phosphorylation and the regulatory T-cell compartment. Treatment targeting a cytokine pathway that signals through STAT3 led to clinical improvement in 1 patient, suggesting a potential therapeutic option for such patients. These results suggest that there is a broad range of autoimmunity caused by germline STAT3 gain-of-function mutations, and that hematologic autoimmunity is a major component of this newly described disorder. Some patients for this study were enrolled in a trial registered at www.clinicaltrials.gov as #NCT00001350. |
DOI | 10.1182/blood-2014-09-602763 |
Alternate Journal | Blood |
PubMed ID | 25359994 |
PubMed Central ID | PMC4304103 |
Grant List | U54 HG006542 / HG / NHGRI NIH HHS / United States U19 HD077693 / HD / NICHD NIH HHS / United States T32 AR007279 / AR / NIAMS NIH HHS / United States U54 HG003273 / HG / NHGRI NIH HHS / United States / / Intramural NIH HHS / United States P30 AR048335 / AR / NIAMS NIH HHS / United States P30 CA091842 / CA / NCI NIH HHS / United States UL1 TR000448 / TR / NCATS NIH HHS / United States KL2 TR001448 / TR / NCATS NIH HHS / United States |